SAN DIEGO, CA, Sept. 24 /PRNewswire-FirstCall/ - NventaBiopharmaceuticals Corporation (TSX:NVN) today announced the publication of invivo results of its lead therapeutic vaccine candidate for the treatment ofhuman papillomavirus (HPV)-related diseases, HspE7, in Clinical and VaccineImmunology, August 2007. The results reported originate from a studyundertaken to characterize the cellular anti-E7 immune response induced byHspE7 and to determine the optimum dosing regimen for inducing effectiveantitumor immunity.
These published study results demonstrated that a single injection ofHspE7 is capable of eliciting long-lasting memory CD8+ T cells and conferringprotection against tumor challenges in mice lacking CD4+ functions. CD8+ Tcells are a type of white blood cell capable of inducing the death of infectedsomatic or tumor cells by killing cells infected with viruses (or otherpathogens) or otherwise damaged or dysfunctional. These data furtherdemonstrated that two HspE7 immunizations protected a higher proportion ofmice for a longer duration.
"These results further strengthen our belief that HspE7 is a promisingimmunotherapeutic agent for treating HPV-related diseases," said Peter Emtage,Ph.D., Vice President, Research and Development at Nventa. "The ability ofHspE7 to induce memory CD8+ T cells in the absence of CD4+ help is significantand suggests that our HspE7 fusion protein may have utility in individualswith compromised CD4+ functions, such as those with invasive cancer and/orhuman immunodeficiency virus infection."
HPV has been detected in most anogenital cancers, and HPV type 16 (HPV16)is closely associated with severe cervical dysplasia and with cervical, analand approximately 25 percent of head and neck cancers. Evidence indicates thatproper immunosurveillance can impede the development of HPV-associated tumorsand that T-cell immunity is important in the resolution and control ofHPV-induced diseases.
About HspE7, Lead Product Candidate:
HspE7 is a novel therapeutic vaccine candidate for the treatment ofdiseases caused by the human papillomavirus (HPV), one of the most commonsexually transmitted diseases in the world. HspE7 is derived from Nventa'sproprietary CoVal(TM) fusion platform, which uses recombinant DNA technologyto covalently fuse stress proteins to target antigens, thereby stimulatingcellular immune system responses. Heat shock proteins (Hsps), also known asstress proteins, are naturally present in the human body and play importantroles in the immune system, including transporting substances within cells andactivating cells of the immune system. Nventa is pursuing clinical developmentof new HspE7 (HspE7 dosed with an adjuvant).
About Nventa Corporation:
Nventa is developing innovative therapeutics for the treatment of viralinfections and cancer, with a focus on diseases caused by the humanpapillomavirus (HPV). The corporation is publicly traded on the Toronto StockExchange under the symbol NVN. For more information about Nventa, please visitwww.nventacorp.com.
This press release contains statements which, to the extent that they arenot recitations of historical fact may constitute forward-looking informationunder applicable Canadian securities legislation or forward-looking statementswithin the meaning of the United States Private Securities Litigation ReformAct of 1995. Such forward-looking statements or information may includefinancial and other projections as well as statements regarding the Company'sfuture plans, objectives, performance, revenues, growth, profits, operatingexpenses or the Company's underlying assumptions. The words "may", "would","could", "will", "likely", "expect," "anticipate," "intend", "plan","forecast", "project", "estimate" and "believe" or other similar words andphrases are i